GlassScriptPhysician profile
Serena Weidner
NPI 1346634268
$3,032.44
in general payments reported to CMS, 2019-2025
19 companies · $669 in 2025
The $669 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $440 · 2022: $721 · 2023: $431 · 2024: $770 · 2025: $669.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,633 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,632.96 |
| Education | $237.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $510.89 | 2022-2025 | Tremfya |
| Sun Pharmaceutical Industries INC. | $394.48 | 2022-2025 | Ilumya |
| Abbvie INC. | $393.97 | 2022-2025 | |
| Genzyme Corporation | $302.73 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $221.31 | 2022-2024 | Sotyktu |
| Janssen Scientific Affairs, LLC | $201.80 | 2021-2022 | |
| Incyte Corporation | $179.40 | 2021-2022 | |
| Lilly USA, LLC | $167.60 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Galderma Laboratories, L.P. | $160.46 | 2021-2025 | Nemluvio |
| Regeneron Healthcare Solutions, INC. | $147.53 | 2023-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $78.07 | 2022-2025 | |
| Organon LLC | $56.82 | 2025 | Vtama |
| Biofrontera INC. | $44.46 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Dermavant Sciences, INC. | $38.83 | 2024 | Vtama |
| Cipher Pharmaceuticals US LLC | $38.52 | 2025 | Spinosad, Natroba |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $35.47 | 2023-2025 | |
| Amgen INC. | $28.72 | 2024 | Otezla |
| Leo Pharma INC. | $17.01 | 2022 | |
| Arcutis Biotherapeutics, INC. | $14.37 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Serena Weidner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.